Ultime notizie per AST SpaceMobile (NASDAQ:ASTS) Azioni

AST SPACEMOBILE INC

AST SpaceMobile

AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.

United Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBCP#NASDAQ">UBCP</a>) reported quarterly earnings of $0.33 per share. This is a 10 percent increase over earnings of $0.30 per share from the same period last year. The company reported $7.985 million in sales this quarter. This is a 8.11 percent increase over sales of $7.386 million the same period last year.

Earnings

News

UBCP

United Bancorp Q2 EPS $0.33 Up From $0.30 YoY, Sales $7.985M Up From $7.386M YoY

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam&#8217;s recent performance highlights the company&#8217;s strong position in <a href="https://www.benzinga.com/pressreleases/25/07/b46753079/alnylam-pharmaceuticals-reports-second-quarter-2025-financial-results-and-highlights-recent-period">the competitive landscape.</a>
<ul class="wp-block-list">
<li>ALNY stock is testing its 52-week high. <a href="https://www.benzinga.com/quote/ALNY" target="_blank" rel="noreferrer noopener">Check the latest price here.</a></li>
</ul>
Alnylam Pharmaceuticals stock is surging on Thursday after the company reported upbeat second-quarter earnings and 2025 guidance.
The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from 56 cents a year ago. Analysts estimated a<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener"> loss of 79 cents</a>.
The company reported quarterly sales of $773.69 million, up 17% year over year, beating the consensus of $638.55 million.
Alnylam Pharmaceuticals achieved global net product revenues for Amvuttra and Onpattro for the second quarter of $492 million and $53 million, respectively, representing $544 million in total TTR net product revenues and 77% total TTR growth compared to a year ago.
The company achieved approximately 1,400 ATTR-CM Patients on Amvuttra (vutrisiran) as of June 30, 2025.
Also Read: <a href="https://www.benzinga.com/news/legal/25/06/45797712/moderna-beats-alnylam-appeal-in-covid-vaccine-patent-case" target="_blank" rel="noreferrer noopener">Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case</a>
The company achieved global net product revenues for Givlaari and Oxlumo for the second quarter of $81 million and $47 million, respectively, representing $128 million in total Rare net product revenue and 24% total Rare growth year over year.
&#8220;Our first full quarter of AMVUTTRA sales in ATTR-CM provided a significant inflection in our TTR franchise revenues, with total net product revenues growing 64% year-over-year. While still early in the launch, we are very encouraged by the initial pace of uptake&#8230;,&#8221; said Yvonne Greenstreet, chief executive officer of Alnylam.
Guidance: &#8220;Based on the strong progress during the first half of 2025 and our confidence in the overall business for the rest of the year, we are raising our total net product revenue guidance range by 27% at the midpoint, driven by an upward revision to our TTR franchise revenue guidance,&#8221; Greenstreet added.
Alnylam raised its fiscal 2025 sales guidance from $2.7 billion-$3 billion to $3.3 billion-$3.55 billion compared to the consensus of $2.89 billion.
Total TTR net product revenues (Amvuttra and Onpattro) of $2.175 billion-$2.275 billion, up from <a target="_blank" href="https://www.benzinga.com/node/45179856" rel="noreferrer noopener">prior guidance of $1.6 billion-$1.725 billion</a>.
Total rare net product revenues (Givlaari and Oxlumo) of $475 million-$525 million, up from prior guidance of $450 million –&nbsp;$525 million.
Needham maintains Alnylam Pharmaceuticals with a Buy and raises the price <a target="_blank" href="https://www.benzinga.com/quote/ALNY/analyst-ratings" rel="noreferrer noopener">forecast from $377 to $478</a>.
Price Action: ALNY stock was up 15.9% at $393.71 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46760627/magnificent-seven-microsoft-meta-nvdia-earnings-sp500-market-cap" target="_blank" rel="noreferrer noopener">Magnificent Seven Now Worth Over $19 Trillion—And They Make Up 35% Of The S&amp;P 500</a></li>
</ul>
Photo: jittawit21/Shutterstock

Biotech

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

ALNY

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

DA Davidson analyst Michael Baker maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Buy and raises the price target from $550 to $585.

Price Target

Analyst Ratings

ULTA

DA Davidson Maintains Buy on Ulta Beauty, Raises Price Target to $585

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and raises the price target from $100 to $112.

DA Davidson Maintains Neutral on Federal Signal, Raises Price Target to $112

WIIM

SIMO

SIMO stock has given up its prior gain. Silicon Motion Technology shares were trading higher after the company reported better-than-expected Q2 financial results.

When a mother named TJ wrote to Suze Orman's "<a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-how-can-i-get-a-mega-retirement-account">Women &amp; Money</a>" podcast for help, she described a difficult situation: her 22-year-old daughter, a full-time student working weekends and part-time hours, had maxed out her credit cards — again.
Two years earlier, the daughter refinanced her car to pay off her credit cards, but following the death of her father, she slipped back into debt and now owes $15,000. Her credit accounts have been closed, and she's locked into a payment plan she can't afford. Struggling to cover even gas and personal expenses, she turned to her mother for help.
TJ said she refuses to help her daughter financially and asked Orman for guidance.
Don't Miss:
<ul class="wp-block-list">
<li>Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a></li>
</ul>
<a href="https://www.benzinga.com/personal-finance/management/25/07/46526633/thinking-about-lending-money-to-family-suze-orman-says-you-might-be-hurting-more-than-helping">Orman</a> didn't hold back. "Do exactly what you have been doing, TJ," she said. "It's just that simple. Obviously, this is a woman who needs to learn until she gets it, and the only way she's going to get it is by letting her suffer."
<h2 class="wp-block-heading">Tough Love, Financial Lessons</h2>
Orman&#8217;s advice may sound harsh, but it's rooted in a principle she has long preached: personal responsibility. For young adults, particularly <a href="https://www.benzinga.com/personal-finance/25/02/43893926/you-can-be-a-student-without-a-student-loan-dave-ramseys-advice-to-paying-cash-for-college">college students</a> or recent graduates, early financial mistakes can leave lasting scars — but they can also be powerful teaching moments. Orman often emphasizes that bailing out a financially irresponsible loved one might only delay the inevitable reckoning.
According to a U.S. News &amp; World Report <a href="https://money.usnews.com/credit-cards/articles/2023-college-student-credit-cards-survey">survey</a>, over 42% of college students carry credit card debt. Many use credit for essentials like books and housing, but nearly half report spending on nonessentials like dining out and impulsive shopping.&nbsp;
In TJ's daughter's case, a mix of emotional spending and financial missteps pushed her into a deep hole.
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
<h2 class="wp-block-heading">Why Credit Card Debt Hits Students So Hard</h2>
Credit cards can be useful tools for building credit, but only when used responsibly. Students are especially vulnerable to making mistakes. A missed or late payment can lead to fees, higher interest rates, and a <a href="https://www.benzinga.com/personal-finance/management/25/06/45972344/millions-of-americans-just-took-a-100-point-hit-to-their-credit-score-and-it-could-get-worse-as-student-loan-collections-resume">drop in credit score</a> — a black mark that can linger for years.
A lack of financial literacy compounds the issue. Only 27% of students surveyed by U.S. News correctly identified what "revolving a balance" means. And nearly one in five didn't realize that credit cards require regular monthly payments.
These misunderstandings can quickly snowball into real financial harm. Even a $2,000 balance on a card with 20% interest could take over two years to pay off with minimum payments — costing hundreds in interest alone.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">What Should Parents Do?</h2>
While TJ's instinct to withhold financial help may seem cold, Orman's response highlights the long-term benefits of letting young adults face the consequences of their choices. That doesn't mean parents can't help at all.&nbsp;
<a href="https://www.morganstanley.com/articles/sage-credit-advice-college-students">Morgan Stanley</a> suggests starting with open conversations about budgeting, the risks of debt, and the value of credit. Teaching financial basics early can help prevent bigger issues later.
Adding a student as an authorized user to a parent&#8217;s card or encouraging responsible use of a student credit card can be helpful — but only if the student understands how credit works.
<h2 class="wp-block-heading">Bottom Line</h2>
Orman's blunt advice isn't about punishment — it's about growth. Letting someone "suffer," as she puts it, may be the push they need to take ownership of their finances. For parents of <a href="https://www.benzinga.com/24/12/42467913/dave-ramsey-warns-against-hammock-parenting-7-2-million-able-bodied-men-arent-even-looking-for-work-and-its-not-their-fault">financially struggling adult children</a>, the lesson is clear: emotional support doesn't have to mean writing a check. Sometimes, the hardest part of helping is stepping back.
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Personal Finance

'The Only Way She's Going To Get It Is By Letting Her Suffer' Suze Orman's Tough Advice For Mother Whose Daughter Maxed Out Her Credit Cards

DA Davidson analyst Gary Tenner maintains Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) with a Buy and raises the price target from $96 to $100.

DA Davidson Maintains Buy on Axos Financial, Raises Price Target to $100

DA Davidson analyst Manuel Navas maintains NBT Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTB#NASDAQ">NBTB</a>) with a Buy and raises the price target from $53 to $55.

NBTB

DA Davidson Maintains Buy on NBT Bancorp, Raises Price Target to $55

<a href="https://www.cbsnews.com/news/china-iran-us-sanctions-dark-fleet/" title="https://www.cbsnews.com/news/china-iran-us-sanctions-dark-fleet/">https://www.cbsnews.com/news/china-iran-us-sanctions-dark-fleet/</a>

Macro Economic Events

Politics

Global

Economics

Reported Earlier: "China Uses "Dark Fleet" To Buy Oil From Iran And Evade U.S. Sanctions In International Waters" - CBS News

<a href="https://www.benzinga.com/news/entertainment/25/06/46122235/mark-zuckerberg-hated-the-social-network-film-dont-tell-him-a-sequel-is-coming">A sequel to</a> "The Social Network" will likely require recasting the role of Mark Zuckerberg. 
What Happened: Jesse Eisenberg, who portrayed Zuckerberg in &#8220;The Social Network,&#8221; has reportedly declined to reprise the role. 
Jeremy Allen White, best known for acting roles on "Shameless" and "The Bear," is in talks to play the Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO, according to a <a href="https://variety.com/2025/film/news/mikey-madison-jeremy-allen-white-social-network-sequel-1236475144/">report </a>from Variety. 
Mikey Madison, who won the Best Actress Academy Award last year for &#8220;Anora,&#8221; is also in talks for a role.
According to the report, writer and director Aaron Sorkin, who wrote the screenplay of the original 2010 film, met with both Madison and White about roles in the film.
Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>), which produced &#8220;The Social Network,&#8221; has not officially announced the project. 
Sony declined to comment to Variety. 
David Fincher directed the 2010 film; he is not expected to return for the sequel.
White has received critical acclaim and awards for his role on "The Bear." He also took on the role of legendary musician Bruce Springsteen in the biopic, "Deliver Me from Nowhere." The film is set for an Oct. 24, 2025 theatrical release and will feature White singing all the songs.
The actor could end up playing a character different than Zuckerberg, as it said he was in line for a lead role, but didn't specify which character.
Meanwhile, the Hollywood Reporter <a href="https://www.hollywoodreporter.com/movies/movie-news/the-social-network-jeremy-strong-mark-zuckerberg-1236334480/">reports</a> that actor Jeremy Strong is also being considered to play Zuckerberg.
Strong is best known for his role on "Succession" and in the recent Donald Trump biopic "The Apprentice.&#8221;
Read Also: <a href="https://www.benzinga.com/news/entertainment/25/07/46620076/elon-musk-biopic-who-should-play-tesla-ceo-grok-picks-these-6-actors">Elon Musk Biopic: Who Should Play Tesla CEO? Grok Picks These 6 Actors</a>
Why It's Important: &#8220;The Social Network&#8221; focused on the early creation days of Meta Platforms, then known as Facebook. Eisenberg portrayed Zuckerberg in his early years as co-founder of the company.
The new film will center on a series of articles published by the Wall Street Journal in 2021. The so-called "Facebook Files" exposed the company as a harmful platform for children and teens, along with being a source of misinformation.
The film may also explore Facebook's alleged role in misinformation contributing to political violence like the Jan. 6, 2021 attack on the U.S. Capitol.
"The Social Network" earned eight Academy Award nominations and saw Sorkin win for Best Adapted Screenplay. The film grossed $97 million domestically and $225 million worldwide at the box office, according to Box Office Mojo.
Zuckerberg <a href="https://www.benzinga.com/news/21/10/23381351/5-things-you-might-not-know-about-facebooks-mark-zuckerberg-2">was not a fan</a> of "The Social Network" and will likely distance himself from the sequel.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">Top Anticipated 2025 Movies For Big Screen Success And Stocks Investors Should Watch</a></li>
</ul>
Image: Shutterstock

Entertainment

SONY

Mark Zuckerberg On Big Screen: Here's Who Could Play Meta Platforms CEO Next

CPOP

Pop Culture Group Shares Resume Trading

SBUX

Reuters Cites HegdePoint Global Markets Saying U.S. Tariffs On Coffee Could Impact Demand, Reducing Global Deficit In 2024/25 Season; Global Coffee Market Deficit In 2024/25 Could Fall To 1.7M Bags, Down From 3.5M Bags Outlook Without Tariffs Impact

Pop Culture Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 166.6%

Update : Wedbush analyst Scott Devitt maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Outperform and raises the price target from $750 to $920.

Update : Wedbush Maintains Outperform on Meta Platforms, Raises Price Target to $920

SPOT

Spotify Technology shares are trading lower on continued weakness after the company reported worse-than-expected Q2 financial results on Tuesday and received several analyst price target cuts on Wednesday.

https://www.unifor.org/news/all-news/unifor-members-ratify-new-contract-rio-tinto#:~:text=The%20union's%20bargaining%20committee%20secured,Rio%20Tinto%20Alcan%20Pension%20Plan.

Unifor Members Ratify New Contract With Rio Tinto; Union's Bargaining Committee Secured Wage Increases Of More Than 16% Over The Term Of The Four-year Agreement

DA Davidson analyst Rudy Kessinger maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Buy and lowers the price target from $32 to $24.

CFLT

DA Davidson Maintains Buy on Confluent, Lowers Price Target to $24

Silexion Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) released new preclinical data on Thursday, revealing inhibition rates of up to 97% in pancreatic cancer cells and almost 90% in <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">colorectal cancer cells</a>.
These findings include the company's first evidence of efficacy against the clinically significant KRAS Q61H <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46757839/silexion-therapeutics-announces-new-preclinical-data-showing-up-to-97-inhibition-of-cancer-cell-gr" rel="noreferrer noopener">mutation in human cancer cells</a>.
<h2 class="wp-block-heading">Key Findings</h2>
SIL204 demonstrated dose-dependent inhibition of up to 94% in pancreatic cancer cells harboring KRAS G12D mutations at nanomolar concentrations.
SIL204 showed comparable efficacy of approximately 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations, a variant not previously reported in the company's studies.
SIL204 produced an inhibition rate of nearly 90% in colorectal cancer cells with KRAS G12D mutations, extending previous evidence of its effectiveness beyond pancreatic cancer
The announcement comes just days after Silexion reported significant efficacy of SIL204 in lung cancer cell lines, validating the company's innovative lipid-conjugated delivery system.
In July, Silexion shared new preclinical data demonstrating SIL204's significant efficacy in human <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46316927/silexion-therapeutics-announces-positive-results-in-preclinical-study-demonstrating-significant-si" rel="noreferrer noopener">lung cancer cell lines</a>.
The study revealed significant dose-dependent inhibition in lung cancer cells harboring KRAS G12D mutations, with notable efficacy, highlighting SIL204's potential as a versatile therapeutic for lung cancer.
The results also support Silexion's lipid-conjugated delivery system for enhancing SIL204 drug entrance into tumor cells.
Silexion continues to prepare for the initiation of a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for the treatment of KRAS-driven solid tumor cancers, leveraging both intratumoral and systemic delivery approaches as part of the company's dual-route administration strategy.
<h2 class="wp-block-heading">How To Buy SLXN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Silexion Therapeutics' case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Price Action: SLXN stock is up 30.10% at $14.72 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46765438/xeroxs-2025-margin-cut-undermines-transformation-hopes" target="_blank" rel="noreferrer noopener">Xerox's 2025 Margin Cut Undermines Transformation Hopes</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

SLXN

Why Is Silexion Therapeutics Stock Trading Higher On Thursday?

HOOD

Robinhood Markets shares are trading lower following the release of its Q2 financial results.

Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) delivered <a href="https://www.benzinga.com/markets/equities/25/07/46748601/lam-research-stock-dips-over-5-in-premarket-trading-whats-happening">stronger-than-expected earnings</a> and raised its full-year guidance, driven by robust demand from China that defied broader industry headwinds. 
However, despite the upbeat tone and improved outlook, shares of the chipmaking equipment giant fell more than 5% in Thursday trading, as investors questioned the durability of growth driven largely by a geopolitically sensitive region.
In its fiscal fourth quarter, Lam reported adjusted earnings of $1.33 per share on revenue of $5.171 billion, both figures surpassing Wall Street estimates of $1.20 and $4.997 billion, respectively. 
Also Read: <a href="https://www.benzinga.com/markets/tech/25/07/46367170/why-lam-research-outpaced-market-with-40-gain-in-2025" target="_blank" rel="noreferrer noopener">Why Lam Research Outpaced Market With 40% Gain In 2025</a>
The company also issued an optimistic forecast for the first quarter of fiscal 2026, projecting adjusted EPS in the range of $1.10 to $1.30 on revenue between $4.9 billion and $5.5 billion, well above consensus estimates of $0.98 and $4.607 billion.
Driving the outperformance was a sharp uptick in orders from China, prompting Lam to revise its 2025 wafer fabrication equipment (WFE) market forecast upward from $100 billion to $105 billion. Analysts noted that the company's momentum in China now sets it apart from peers, particularly as consensus had expected the region's WFE spend to decline this year.
Needham analyst Charles Shi, who maintained a Buy rating and lifted his <a href="https://www.benzinga.com/quote/LRCX/analyst-ratings">price forecast</a> from $110 to $115, described the quarter as a "strong beat-and-raise," underscored by demand in China and renewed multinational investment.
According to Shi, China accounted for over 35% of Lam's revenue in the second quarter, up from 31% in the first quarter, and is expected to remain at that level in the third quarter.
Shi also pointed to a $700 million sequential increase in deferred revenue as a clear sign of an expanding backlog, with over $1 billion in China-related orders expected to be fulfilled in the second half of 2025. 
However, management's early read on the calendar fourth quarter suggests a potential revenue pullback toward earlier-year levels, signaling that the China-driven surge may be nearing its peak. This dynamic, Shi warned, could add fuel to ongoing concerns that Lam is "overearning" in the Chinese market.
Still, Shi raised his 2025 EPS estimate by 4% and bumped his 2026 revenue forecast by 2%, citing the stronger-than-expected baseline. Yet he acknowledged the market's growing skepticism over whether Lam's performance represents structural strength or a short-lived spike in demand.
Goldman Sachs analyst James Schneider echoed that ambivalence. While reiterating a Buy rating and $115 price forecast, Schneider noted that Lam's results were impressive across the board, not merely a China story. 
He acknowledged investor positioning had already been bullish heading into the print, possibly limiting the upside reaction despite the beat.
Schneider highlighted rising demand in both logic and memory segments as contributing to the revenue beat. China sales rose to 35% of total revenue, supported by both domestic firms and record multinational investments. 
Lam's updated WFE forecast is in line with Goldman's projections, and the company expects spending in the second half of 2025 to remain flat versus the first half.
Looking ahead, Schneider believes Lam is well-positioned to outperform peers, thanks to its strong foothold in deposition and etch technologies, critical processes in advanced semiconductor manufacturing, as well as its exposure to NAND and High Bandwidth Memory (HBM). 
He sees the company's NAND upgrade momentum, particularly as memory suppliers increase layer counts, as a structural tailwind through 2026.
Price Action: LRCX stock is trading lower by 5.10% to $94.02 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46756444/comcast-rides-high-on-theme-park-and-peacock-success" target="_blank" rel="noreferrer noopener">Comcast Rides High On Theme Park And Studio Success</a></li>
</ul>
Image via Shutterstock

Reiteration

Tech

ASML

LRCX

Lam Research Projects Strong FY26, But China-Driven Growth Faces Market Skepticism

Press Releases

AST SpaceMobile Secures Additional $100.0 Million of Liquidity from Non-Dilutive Equipment Financing

Fintech

Mutual Funds

Markets

Tradr Prepares Five Leveraged Single-Stock ETF Launches

Opinion

Tradr Launches First-to-Market Leveraged ETFs on CoreWeave, AST SpaceMobile, Constellation Energy, GE Vernova and NuScale Power

Options Trading Now Available on Latest Five Tradr ETFs: CWVX, SMU, ASTX, GEVX and CEGX

AST SpaceMobile Announces Proposed Repurchase of up to $135.0 Million Convertible Senior Notes to be Funded by Concurrent Registered Direct Offering of Class A Common Stock

AST SpaceMobile Announces Proposed Private Offering of $500.0 Million of Convertible Senior Notes Due 2032

AST SpaceMobile Announces Pricing of Private Offering of $500.0 Million of Convertible Senior Notes Due 2032 (Effective Conversion Price of $120.12 per Share with Capped Call)

AST SpaceMobile Prices Repurchase of Convertible Senior Notes to be Funded By Concurrent Registered Direct Offering of Class A Common Stock

AST SpaceMobile to Provide Quarterly Business Update on August 11, 2025

AST SpaceMobile Announces Closing of Private Offering of $575.0 Million of Convertible Senior Notes Due 2032

Comments

AST SpaceMobile

Notizie

Ultime notizie per AST SpaceMobile (NASDAQ:ASTS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO